Amgen announced that the U.S. Food and Drug Administration (FDA) has accepted a Biologics License Application (BLA) and granted Priority Review for tezepelumab in the treatment of asthma. Tezepelumab is being developed by Amgen in collaboration with AstraZeneca.

The National Institute of Epidemiology (NIE) was established on July 2, 1999 by merging the Central JALMA Institute for Leprosy (CJIL Field Unit), Avadi with the Institute for Research in Medical Statistics (IRMS), Chennai. The broad objectives of the Institute cover Development of human resources in epidemiology and bio-statistics, Networking of the various ICMR and non-ICMR Institutes at the national level for epidemiological purposes, and Consultancy.

Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER) can trace its origins to the Ecole de Medicine de Pondicherry established by the French Government in 1823. In 1956 foundation for new medical college was laid and in 1964, hospital was inaugurated. JIPMER became an institution of national importance under the Ministry of Health and Family Welfare, Government of India in the year 2008. It is an institution established for teaching, research and patient care in the area of health. JIPMER spreads over 192 acres.

The Central Council for Research in Ayurvedic Sciences (CCRAS) is an autonomous body of the Ministry of AYUSH (Ayurveda, Yoga & Naturopathy, Unani, Siddha and Homeopathy), Government of India. It is an apex body in India for the formulation, coordination, development and promotion of research on scientific lines in Ayurveda and Sowa-Rigpa system of medicine.

Indian Institute of Science Education and Research Mohali envisions a new generation of scientists dedicated to the pursuit of knowledge in  frontier areas of basic sciences. In an intellectually vibrant academic environment, IISER Mohali nurtures the basic tenets of science education and research at undergraduate and postgraduate levels. In so doing, the institute aims to emerge as a global centre of learning, academic excellence, and innovative research.

At Cipla, we constantly work towards ensuring access to high quality and affordable medicines to support patients in need. Which is why, we have been trusted by health care professionals and patients across geographies for the last 8 decades.

Campus Drive 2021
Organised by
N N Sattha College of Pharmacy Ahmednagar

MSN Group is one of the fastest growing manufacturers of Active Pharmaceutical Ingredients (APIs) and Finished dosages in India. Established in the year 2003, MSN Group comprises of 330 API manufacturing plants (including one for Oncology), three finished dosage facility ( including one for Oncology)and a dedicated R&D Center . Our plants are ISO 9001-2000 certified, WHO: GMP, EU:GMP and USFDA approved.

API DIVISION : R&D DEPARTMENT

Vital Therapeutics and Formulations Private Limited is an endeavour to offer trustworthy partnership comprising superior quality products and services par excellence in Contract Manufacturing, Animal Nutrition, Human Nutrition, Aquaculture and Vitamin pre-mixes.

QC - Male
Qly : B. Pharmacy & MSc
Exp : 2 to 3 years
Skill : Handling of HPLC - Analysis

Cipla, as an organisation has been built brick-by-brick on the foundation of care. Caring For Life has always been and continues to remain, our guiding purpose. Driven by the same purpose, we have extended our presence to 80+ countries providing over 1,500 products across various therapeutic categories in 50+ dosage forms. To make healthcare more affordable globally, we are deepening our presence in the key markets of India, South Africa, the U.S. among other economies of the emerging world.

Indoco Remedies Ltd., is a fully integrated, research-oriented pharma company engaged in the manufacturing and marketing of Formulations and Active Pharmaceutical Ingredients (APIs). We have seven decades of presence in the Indian Pharma market and a strong foothold in the international market across 55 countries. Indoco, a USD 166 million company, employs around 6000 personnel, including over 300 skilled scientists.

Bioplus is a family majority owned business with over 500 employees, multiple manufacturing sites and business in over 50 countries. Our products are focused on naturally sourced, renewable resource compounds validated by advanced science. Our focus is on licensed and OTC (nutritional) pharmaceuticals or healthcare products, novel drug delivery, excellence in carbohydrate chemistry and biopharmaceuticals.

The goal of the trial, known as HIV-CORE 0052, is to evaluate the safety, tolerability, and immunogenicity of the HIVconsvX vaccine – a mosaic vaccine targeting a broad range of HIV-1 variants, making it potentially applicable for HIV strains in any geographical region.

Thirteen healthy, HIV-negative adults, aged 18-65 and who are considered not to be at high risk of infection, will initially receive one dose of the vaccine followed by a further booster dose at four weeks.

AstraZenecas proposed acquisition of Alexion Pharmaceuticals, Inc.has achieved an important step towards completion by having cleared the European Commission review.

The clearance follows competition clearances in the United States, Japan and other countries globally, with a complete list available on astrazeneca.com. Regulatory clearance in the UK is pending and remains a requirement to complete the deal.

Merck known as MSD outside the United States and Canada, announced that the U.S. Food and Drug Administration (FDA) has approved an expanded label for KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy for the treatment of patients with locally advanced cutaneous squamous cell carcinoma (cSCC) that is not curable by surgery or radiation.

Alvotech, the Iceland-based biosimilar company, announced that the first patient has been dosed in the comparative, confirmatory efficacy and safety clinical study (AVT04-GL-301) for AVT04, Alvotech‘s proposed biosimilar to the reference product Stelara®. The objective of the study is to demonstrate therapeutic equivalence between AVT04 and Stelara® in terms of safety, efficacy and immunogenicity in patients with moderate-to-severe chronic plaque psoriasis.

Employees State Insurance Corporation of India is an integrated social security system tailored to provide social protection to workers,immediate dependent or family, in the organised sector, in contingencies, such as, sickness, maternity and death or disablement due to an employment injury or occupational hazard. The ESI Scheme is mainly financed by contributions raised from employees covered under the scheme and their employers, as a fixed percentage of wages.

IGIMS was established on 19th November 1983, as an autonomous organisation on the pattern of All India Institute of Medical Sciences, New Delhi. The objective was to provide super specialty medical facilities in Bihar. On 27th January 1983 Cabinet approved the completion of this massive project in 4 phases within a span of six (6) years. According to the decision of State Government, 130.20 Acres of land was transferred to IGIMS.

Appointment is to be made on vacant contract posts in various national health programs under National Health Mission, Mahasamund.  The details of the contractual posts to be recruited are as follows.

Post : Pharmacist (RBSK)

In 1870 the Maharaja of Vijanagaram first floated the idea of starting a Medical College in Lucknow. But the idea was watered down due to paucity of funds. In 1905 the visit of King-Emperor, George V, then Prince of Wales, inspired the idea of establishing a college to commemorate the occasion. The originator of this fine ideal to commemorate the occasion was late Raja Sir Tassadnq Rasul Khan of Jehangirabad to whom Sir Harcourt Butler wrote on 1st December 1905.